fda tirzepatide news Grants a New Indication for Obesity Management FDA's tirzepatide decision creates uncertainty

Patient-specific compounding still exists in narrow situations, but the vast online market that sold "compounded GLP-1" through 2024 has been the subject of dozens of FDA warning letters, hundreds of adverse event reports, and an ongoing regulatory crackdown

However, it may cause side effects, including: Nausea Stomach discomfort Vomiting Loss of appetite Diarrhea Constipation Abdominal pain Bloating These effects typically do not require medical consultation and disappear as your body adjusts

Structural formula: MOUNJARO is a clear, colorless to slightly yellow, sterile solution for subcutaneous use

Page Sources FastStats